Managers / Q1 2023 · view latest →
New England Research & Management, Inc.
CIK 0001596077 · 53 W. JACKSON BLVD., SUITE 603, CHICAGO, IL, 60604 · 3122121704
Summary
New England Research & Management, Inc. reported $170,482 in U.S.-listed holdings across 143 positions for Q1 2023.
Its largest position, CHD, represents 3.1% of the portfolio.
Compared with Q4 2022, the fund opened 28 new positions and exited 37.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 76.2% · $129,831
- Other · 20.8% · $35,412
- ADR · 1.7% · $2,845
- REIT · 1.4% · $2,394
Quarter-over-Quarter Changes full breakdown →
vs Q4 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SCHWCharles Schwab | NEW | +30.3K | 30.3K | +$1,587 | $1,587 |
| LyondellBasell Industries | NEW | +16.0K | 16.0K | +$1,505 | $1,505 |
| DLTRDollar Tree Inc. | NEW | +10.0K | 10.0K | +$1,439 | $1,439 |
| Chubb | NEW | +6.9K | 6.9K | +$1,346 | $1,346 |
| BALLBall | NEW | +21.1K | 21.1K | +$1,161 | $1,161 |
| LOWLowes | NEW | +5.2K | 5.2K | +$1,045 | $1,045 |
| PCARPaccar | NEW | +12.7K | 12.7K | +$931 | $931 |
| Biomarin Pharmaceutical | NEW | +9.6K | 9.6K | +$929 | $929 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2023
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q2 2026 | $257M | 134 | Jul 9, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q1 2026 | $237M | 143 | May 7, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $229M | 144 | Jan 7, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | Under review | 146 | Oct 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $210,518 | 147 | Jul 9, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $196,866 | 146 | Apr 16, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $196,512 | 143 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $213,051 | 158 | Oct 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $208,206 | 164 | Jul 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $203,780 | 158 | Apr 16, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $188,796 | 155 | Feb 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $175,496 | 149 | Oct 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $172,393 | 133 | Jul 5, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $170,482 | 143 | Apr 6, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | Under review | 152 | Jan 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $159M | 157 | Oct 6, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $172M | 149 | Jul 20, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $193M | 156 | Apr 20, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $207M | 177 | Jan 5, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $191M | 174 | Oct 8, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $193M | 171 | Jul 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $182M | 167 | Apr 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $162M | 150 | Jan 7, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $138M | 133 | Oct 8, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $140M | 141 | Jul 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $149M | 151 | Jan 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $138M | 157 | Nov 4, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $147M | 163 | Jul 9, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $148M | 164 | Apr 3, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $127M | 152 | Jan 11, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.